Zeleciment rostudirsen (z-rostudirsen)

Name: Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Humanistic burden and health-related quality of life
Published: 2026-09-14T15:39:06-04:00

Duchenne muscular dystrophy

Also known as DYNE-251

Manufacturer: Dyne Therapeutics
Regulatory submission: BLA submitted May 2026
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Burden of Duchenne muscular dystrophy

Humanistic burden and health-related quality of life

3 evidence topics · 3 sources

Caregiver burden

“Anxiety and depression, recorded in up to 70 % of caregivers depending on patients' health and mental status” (opens the source at this quote in a new tab)

Family-caregiver health-state utilities

“Mean utility scores were highest for HS1 (early ambulatory: 0.717) and lowest for HS8 (no hand-to-mouth function, full-time ventilation: 0.477).” (opens the source at this quote in a new tab)

Disease-specific utility measurement

“DMD-QoL utilities did not vary meaningfully across health states compared with HUI-2 scores, which tended to decline with deteriorating mobility.” (opens the source at this quote in a new tab)